Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of cjc 1295 no dac in China. Welcome to wholesale bulk high quality cjc 1295 no dac for sale here from our factory. Good service and reasonable price are available.
CJC 1295 NO DAC is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate endogenous growth hormone (GH) secretion through selective interaction with the pituitary gland's GHRH receptors. Unlike its DAC-modified counterpart, this peptide lacks drug affinity complex (DAC) conjugation, resulting in a shorter half-life and more pulsatile GH release that mimics the body's natural secretion pattern. Its primary mechanism involves binding to GHRH receptors, activating intracellular cAMP pathways to enhance somatotroph activity and amplify pulsatile GH output without disrupting hypothalamic feedback regulation. The peptide's truncated structure (comprising the first 29 amino acids of GHRH with stabilizing modifications) ensures receptor specificity while resisting rapid enzymatic degradation.
|
Customized Bottle Caps And Corks:
|
|
CJC1295 COA
The core difference between DAC and No DAC
CJC-1295, as a synthetic growth hormone-releasing hormone (GHRH) analogue, has significant differences in chemical structure, half-life, mechanism of action and clinical application between its DAC (Drug Affinity Complex) version and the version without DAC. The following presents a comparative analysis from multiple dimensions:
Chemical Structure and Modification Mechanism
Basic Structure
CJC-1295 consists of 29 amino acids and is a modified version of the natural GHRH (1-29 fragment). By optimizing the amino acid sequence (such as replacing the second tyrosine with D-alanine), its stability is enhanced.
Non-DAC version (CJC-1295 NO DAC): Only contains the modified GHRH analogue and does not attach any molecules that extend the half-life.
DAC version (CJC-1295 DAC): Based on CJC-1295, a DAC group (a complex composed of polyethylene glycol and fatty acid derivatives) is covalently linked to it, enabling it to bind to plasma albumin.
Modification Purpose
The introduction of DAC aims to prolong the drug's retention time in the blood circulation through the "albumin capture" mechanism. Albumin is the most abundant protein in plasma. After the DAC group binds to albumin, it can reduce renal filtration and enzymatic degradation, thereby significantly extending the half-life.
Pharmacokinetic Differences
Half-life and duration of action
Without DAC version: The half-life is approximately 30 minutes, and multiple injections (usually 2-3 times per day) are required to maintain an effective concentration. Its action mode is more similar to the physiological pulsatile release of GHRH, suitable for simulating the natural secretion rhythm of growth hormone (GH).
DAC version: The half-life is extended to 6-8 days, and a single injection can continuously stimulate GH secretion for up to 14 days. Its long-lasting characteristic stems from the dynamic binding and dissociation process of the DAC group with albumin, forming a drug "storage depot".
Blood drug concentration curve
Without DAC version: The blood drug concentration shows a rapid rise-fall curve, with a clear peak but a short duration, requiring frequent injections to maintain efficacy.
DAC version: The blood drug concentration fluctuates smoothly, remaining above the therapeutic threshold for a long time, reducing the frequency of injections while minimizing the side effects related to concentration fluctuations (such as a decrease in GH pulse amplitude leading to reduced tissue stimulation).
Physiological Effects and Clinical Applications
GH secretion pattern
Without DAC version: It is more similar to the physiological GH pulsatile release, promoting the release of GH from the anterior pituitary through simulating the intermittent secretion of GHRH in the hypothalamus. This pulsatile stimulation helps maintain the sensitivity of GH receptors and avoids receptor downregulation caused by long-term constant stimulation.
DAC version: It continuously provides GH stimulation signals, although the total GH secretion increases, the pulse amplitude decreases. Long-term use may lead to GH receptor desensitization, requiring a "hormone holiday" (stopping medication for 3-6 months every 3-6 months) to restore receptor sensitivity.
Metabolism and tissue effects
Common effects: Both can increase GH and insulin-like growth factor-1 (IGF-1) levels, promoting protein synthesis, fat breakdown, bone density increase, and cell repair.
Differences: The without DAC version is more similar to the physiological rhythm, performing better in improving sleep quality and promoting muscle memory recovery; the DAC version, due to its long-lasting characteristic, is more suitable for scenarios requiring long-term maintenance of GH levels (such as severe GH deficiency).
Safety and Side Effects
Local reactions
Without DAC version: Due to the need for frequent injections, the incidence of local reactions (such as erythema and induration) is higher.
DAC version: The injection frequency is reduced, and local reactions are decreased, but the DAC group may cause rare allergic reactions (such as rash, itching).
Systemic toxicity
Neither shows liver toxicity or significant prolactin secretion (different from GHRP peptides), but the DAC version, due to its long-lasting characteristic, needs to be vigilant about the side effects of excessive GH secretion (such as joint pain, edema, insulin resistance) caused by excessive GH secretion.
Risk of resistance
Without DAC version: The pulsatile administration mode can reduce the risk of GH receptor downregulation, and the development of resistance is slower.
DAC version: Long-term constant stimulation may accelerate receptor desensitization, and strict adherence to the "hormone holiday" plan is required.
Use Strategies and Optimization Plans
Dose and frequency
Without DAC version: The recommended dose is 100-200 μg per injection, 2-3 times per day, injected before meals or on an empty stomach to enhance absorption.
DAC version: The recommended dose is 2 mg per injection, injected once every 7-14 days, used before bedtime to synergize with the natural peak of GH secretion at night.
Combination therapy
Both can be combined with GHRP (such as GHRP-2, GHRP-6 or Ipamorelin) to significantly enhance GH release through synergistic effects. GHRP inhibits the release of somatostatin, further amplifying the stimulating effect of CJC-1295.
Special scenarios application
Without DAC version： Suitable for athletes for short-term muscle gain and fat loss before competitions, or scenarios requiring rapid recovery (such as wound healing, bone injury repair).
DAC version： More suitable for chronic disease management (such as senile GH deficiency, AIDS-related fat metabolism disorder), or anti-aging treatment requiring long-term maintenance of GH levels.
The precise regulatory potential of short-acting peptides
CJC 1295 NO DAC, as a short-acting growth hormone-releasing hormone (GHRH) analogue, demonstrates precise pulsatile stimulation potential in the field of biological regulation due to its unique chemical structure and metabolic characteristics. Its core advantage lies in achieving refined intervention in metabolism, repair, and growth processes by mimicking the physiological secretion rhythm of growth hormone (GH).
Chemical Structure and Half-Life Characteristics
CJC-1295 NO DAC is a modified version of GHRH (fragment 1-29). By optimizing the amino acid sequence (such as replacing the tyrosine at position 2 with D-alanine) to enhance stability, while not attaching a drug affinity complex (DAC), this design maintains the active region characteristics of the natural GHRH molecule, but significantly extends the half-life to 6-8 hours, far exceeding the few minutes of the natural GHRH.
Although still a short-acting peptide, its half-life is sufficient to support a pulsed administration schedule of 1-3 injections per day, forming a fluctuating curve that closely matches the physiological GH secretion.
Physiological Advantages of Pulsatile Stimulation
Maintenance of GH Receptor Sensitivity
The endogenous GH secretion is in a pulsatile pattern, and the receptor needs time to regain sensitivity after a single pulse. CJC 1295 NO DAC mimics this rhythm through its short-acting property, avoiding the risk of receptor downregulation caused by continuous high-concentration stimulation in the DAC version. Experiments show that the non-DAC version, when injected once, can increase plasma GH levels by 2-10 times for 6 days, while IGF-1 levels increase by 1.5-3 times for 9-11 days, with a pulse amplitude and frequency closer to the natural state.
Precision of Metabolic Regulation
The fat breakdown and protein synthesis effects of GH are highly dependent on the pulse amplitude. CJC-1295 NO DAC, by controlling the injection interval (such as once every 8 hours), can maintain the baseline level of GH increase while retaining the stimulating effect of the pulse peak on lipase activity.
Potential for Synergistic Enhancement of Regulation
Synergistic effect with GHRP
CJC-1295 NO DAC, as a GHRH analogue, can be combined with growth hormone release peptide (GHRP, such as Ipamorelin or GHRP-6). GHRP inhibits somatostatin release and relieves the inhibition of the pituitary gland, while CJC-1295 NO DAC directly stimulates GH secretion, forming a "double switch" effect.
Combined use can increase the pulse amplitude of GH by 200%-300%, while reducing cortisol and prolactin secretion and reducing side effects.
Regulation of Sleep-Wake Cycle
GH secretion is related to the depth of slow-wave sleep. The short-acting property of CJC-1295 NO DAC enables it to enhance the nocturnal GH pulse through a single injection before sleep (200-300 μg), promoting an increase in the duration of deep sleep by 40%-60%.
This regulation not only accelerates tissue repair but also improves the circadian rhythm by regulating the hypothalamic-pituitary-adrenal axis.
Precise Adaptation for Application Scenarios
Anti-aging and Tissue Repair
In aging models, CJC 1295 NO DAC has shown significant effects in anti-aging and tissue repair when administered via daily 2 injections at 12-hour intervals. Specifically, it can effectively increase the collagen synthesis rate of the skin by 25%, which helps improve skin elasticity and reduce the appearance of fine lines and wrinkles. Meanwhile, it promotes bone metabolism and increases bone density by 1.8% per year, providing better support for the skeletal system. Additionally, this peptide can reduce the level of inflammatory factor IL-6 by 30%, thereby alleviating chronic low-grade inflammation associated with aging.
Its short-acting property is a key advantage, as it avoids the risk of joint swelling and insulin resistance that may be caused by long-term exposure to high-concentration growth hormone (GH).
Optimization of Exercise Recovery
For athletes and fitness enthusiasts, CJC 1295 NO DAC is widely used to optimize exercise recovery through a targeted administration strategy: "high pulse on training days + low-dose on rest days". On training days, 100 μg is injected every 8 hours to rapidly stimulate muscle protein synthesis, speed up the repair of damaged muscle fibers, and enhance muscle recovery efficiency. On rest days, a daily injection of 200 μg is adopted to maintain basic tissue repair and support continuous physical recovery.
This scientific strategy not only shortens the recovery time of muscle damage by 40% but also avoids the water and sodium retention issue often associated with the DAC version of CJC 1295, ensuring a more natural and healthy recovery process.
Sleep Quality Improvement
CJC 1295 NO DAC also plays a positive role in improving sleep quality, especially for people with sleep disorders related to hormone imbalance. As a synthetic peptide simulating growth hormone-releasing hormone (GHRH), it can stimulate the pituitary gland to release growth hormone in a physiological pulsatile manner, which is closely related to the human sleep-wake cycle. Administered 30-60 minutes before bedtime, it helps enhance the peak secretion of GH during nighttime deep sleep, prolongs the duration of slow-wave sleep (the most restorative stage of sleep), and reduces nighttime awakenings.
Clinical feedback shows that regular use can shorten sleep onset time by 15-20% and improve sleep continuity, enabling users to wake up more refreshed and alleviating daytime fatigue caused by poor sleep. Its short-acting feature ensures that GH levels return to normal during the day, avoiding potential interference with daytime activities.
Safety and Tolerance Advantages
Reduced Local Reactions
The absence of the DAC structure reduces the tissue deposition after binding with albumin, and the incidence of hard nodules at the injection site drops from 15%-20% in the DAC version to below 5%.
Drug Resistance Management
Through the "hormone holiday" strategy (stopping medication for 2-4 weeks every 3 months), the sensitivity of GH receptors can be fully restored. The non-DAC version, due to its pulsatile stimulation characteristic, has a slower rate of receptor downregulation by 60% compared to the DAC version, further extending the effective usage period.
CJC 1295 NO DAC, through its short-acting property and pulsatile stimulation mechanism, provides precise intervention tools for metabolic regulation, tissue repair, and anti-aging. Its synergistic scheme with GHRP, sleep cycle adaptability, and drug resistance management advantages make it a highly promising molecule in current peptide hormone regulation research. Future research can further explore its cross-regulatory network with thyroid hormones and gonadal hormones to expand the application scope.
In summary, CJC-1295 NO DAC is a complex and multifaceted compound with significant potential in the fields of medicine and sports science. However, its use must be approached with caution, and further research is needed to fully elucidate its mechanisms of action, safety profile, and therapeutic applications.
FAQ
Is CJC better with or without DAC?
+
-
CJC-1295 DAC vs. CJC-1295 (No DAC) is a choice between sustained/continuous growth hormone (GH) release (DAC) or natural, pulsatile spikes (No DAC), differing mainly in their half-life and dosing frequency, with DAC lasting days (once-weekly dosing) versus No DAC lasting minutes/hours (multiple daily dosing), making No DAC often preferred for mimicking natural rhythms and potentially avoiding receptor desensitization, while DAC offers convenience. DAC (Drug Affinity Complex) binds to albumin, extending its life; No DAC (Modified GRF 1-29) is shorter-acting, mimicking natural GH pulses better.
What are the benefits of CJC-1295 no DAC with Ipamorelin?
+
-
The 2x Blend: CJC-1295 (No DAC) 5mg / Ipamorelin 5mg combines two synergistic peptides designed to naturally stimulate the body's production of growth hormone. This blend supports recovery, metabolism, and overall vitality without introducing synthetic hormones.
Hot Tags: cjc 1295 no dac, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Cosmetic, DERMORPHIN, dermorphin in humans, dermorphin peptide, Melanotan ii powder